Patent: 10,350,178

Summary for Patent: 10,350,178

Title:	Methods and compositions for treatment of demyelinating diseases
Abstract:	Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.
Inventor(s):	Blitzer; Jeremy (San Francisco, CA), McKearn; John (St. Louis, MO)
Assignee:	Pathologica LLC (San Francisco, CA)
Application Number:	16/109,824
Patent Claims:	see list of patent claims

United States Patent 10,350,178: Claims, Strength, and Portfolio Landscape

US Patent 10,350,178 claims methods that use methylglyoxal bis(guanylhydrazone) (MGBG) to prevent progression of multiple sclerosis (MS) and reduce relapse-related symptoms, with multiple dependent claim layers covering oral dosing, dose ranges, and comparative tolerability versus a defined set of MS disease-modifying therapies (DMTs) and specific MS drugs, including fingolimod. The claim set is broad on therapeutic intent and narrow on comparative framing and dosing specifics in dependent claims.

---

What do the claims actually cover?

Core independent claim

Claim 1

• Method of prevention of progression of MS
• Administration of MGBG to a patient in need thereof

This is the central capture element: any clinical use of MGBG framed as “prevention of progression” of MS is within scope, regardless of dose, route, regimen schedule, patient subgroup, or study design, so long as “progression prevention” is a stated intended therapeutic outcome.

Relapse symptom and “clinically significant” outcome claims

Claim 2

• In relapse, MS symptoms are decreased.

Claim 3

• MS symptoms are prevented to a clinically significant or detectable level.

These introduce outcome-based limitations but remain “functional.” They do not define biomarkers, endpoints, or assessment modalities. That creates potential enforceability tension: an accused therapy can argue that symptom changes are not “to a clinically significant or detectable level” under the patent’s implicit measurement scheme.

Progression/flare-up definition and time-based demyelination/mobility framing

Claim 4

• Prevents increased occurrence or severity of flare-ups
• Flare-up characterized by:
  • increased demyelination, or
  • reduced capacity for movement over time

This claim is still functional, but it narrows the narrative of what constitutes a “flare” by linking it to demyelination and functional decline.

Route, dosing, and specific numeric dose ranges

Claim 5

• MGBG administered orally.

Claim 6

• MGBG 20 mg/day to 400 mg/day.

These are the first clear hard technical limitations: route is oral, and dosage is in a wide numeric band.

Comparative tolerability claims vs enumerated DMTs

Claim 7

• Administration occurs concomitant with a reduced incidence of at least one side effect
• Side effect list includes:
  • cytopenia (and immune impairment-related effects),
  • nephrotoxicity, hepatotoxicity, cardiotoxicity,
  • teratogenicity,
  • decreased pulmonary function,
  • macular edema,
  • peripheral neuropathy,
  • severe skin reactions,
  • increased infection risk including latent bacterial/viral,
  • impaired innate/adaptive immunity,
  • flushing
• Comparison set (explicit):
  • interferon beta-1a
  • interferon beta-1b
  • glatiramer acetate
  • peginterferon beta-1a
  • daclizumab
  • teriflunomide
  • fingolimod
  • dimethyl fumarate
  • alemtuzumab
  • mitoxantrone
  • natalizumab

This is the key claim strategy shift: it does not merely claim “MGBG has fewer side effects.” It claims that MGBG administration is “concomitant with” reduced incidence compared to a specific list of comparators. That comparator enumeration can help novelty arguments during prosecution but can also narrow enforceability because an accused party may dispute the comparator set, trial design comparability, or the “incidence reduction” evidence.

Combination therapy layering

Claim 8

• Additionally comprises administration of an agent chosen from:
  • interferon beta-1a/b, glatiramer acetate, mitoxantrone, natalizumab,
  • fingolimod, laquinimod, dimethyl fumarate, teriflunomide.

Claim 9

• The agent is fingolimod.

Claims 10 to 12

• Fingolimod dose options:
  • 0.5 mg/day (Claim 10)
  • <0.5 mg/day (Claim 11)
  • 0.25 mg/day (Claim 12)

This creates a specific combination scenario: oral MGBG plus fingolimod at defined doses.

Further narrowing: reduced side effects subset

Claim 13

• Concomitant with reduced incidence of at least one side effect chosen from:
  • cytopenia, nephrotoxicity, hepatotoxicity, cardiotoxicity, teratogenicity.

Claims 14 to 18

• Cytopenia subset includes:
  • lymphopenia and neutropenia.
• Multiplicity requirement:
  • at least two side effects reduced (Claim 15)
  • specific combinations appear in Claims 17-19.

Claim 19

• Reduced incidence of:
  • cardiotoxicity and teratogenicity
  • plus cytopenia/hepatotoxicity combinations from earlier narrowing steps.

---

How strong are these claims as a patent asset?

Claim scope: broad method, narrow “proof” hooks

• Broad capture (Claims 1-4): The independent method is a prevention-of-progression framing with administration of MGBG. Route/dose not required for Claims 1-4.
• Constrained subsets (Claims 5-6): Oral route and the wide 20-400 mg/day dosing range.
• Evidence-demanding limitations (Claims 7, 13-19): “Reduced incidence” relative to enumerated DMTs requires comparative clinical or at least statistically-supported evidence.
• Combination specificity (Claims 8-12): Addition of fingolimod at numeric doses reduces the number of potential infringement scenarios but increases specificity for enforcement against deliberate combination regimens.

Most enforceable elements (in practice)

The most litigation-relevant limitations are the ones that map to clinical protocols:

• Oral administration (Claim 5)
• Numeric dose range (Claim 6)
• Defined co-therapy regimens including fingolimod and dose (Claims 9-12)
• Constrained side effect reductions (Claims 13-19)

Most vulnerable elements (in practice)

• “Clinically significant or detectable level” (Claim 3) can be attacked as indefinite or as requiring post hoc determination without a defined measurement protocol.
• “Concomitant with reduced incidence” relative to multiple DMTs (Claim 7) can be challenged as requiring head-to-head evidence that many real-world or single-arm scenarios cannot provide.
• The functional definition of flare-ups in Claim 4 (demyelination or reduced movement over time) may require correlating radiologic findings with functional outcomes.

---

What is the likely patent landscape around MGBG for MS?

MGBG (methylglyoxal bis(guanylhydrazone)) is known historically as an anticancer hypoglycemia-inducer and a methylglyoxal-targeting agent, with documented interest in immunometabolic and lymphotoxic mechanisms rather than mainstream MS DMT mechanisms. The patent landscape for MS is heavily populated by:

• interferon-based therapies,
• glatiramer acetate,
• fumarates,
• S1P receptor modulators (including fingolimod),
• integrin targeting (natalizumab),
• CD25 targeting (daclizumab),
• depleters (alemtuzumab),
• synthesis inhibitors (teriflunomide),
• mitoxantrone, and other compounds.

Against that crowded DMT landscape, an MGBG MS-use patent typically faces a standard innovation hurdle:

• whether prior art already disclosed MGBG (or sufficiently close methylglyoxal derivatives) as MS treatment,
• whether there is experimental precedent for MS progression inhibition,
• and whether the comparative safety/toxicity profile is supported by non-obvious data.

Because the user-provided content includes only the claims and not the patent’s specification, priority, prosecution history, cited references, or cited prior art, a complete landscape mapping to specific US applications/publications cannot be derived here without risking inaccuracy.

---

Claim-by-claim risk map for validity and infringement

Claims 1-4 (method outcome framing)

Validity risk

• High risk if any earlier publication describes MGBG in MS patients or MS models with similar outcomes (progression suppression, relapse improvement, reduced demyelination).
• Moderate risk if prior art describes MGBG in autoimmune CNS disease broadly, where MS inclusion could be argued as an obvious adaptation.

Infringement risk

• Moderate: to infringe, an accused regimen must be clearly “administration of MGBG” and framed as preventing progression. If a regimen is trialed for other endpoints or labeled differently, infringement theories can become contested.

Claims 5-6 (oral route and dosing)

Validity risk

• Route and dose range narrow the claim but do not necessarily eliminate prior art if oral MGBG dosing is already disclosed in other contexts (oncology trials) or if MS model doses map into this band.

Infringement risk

• Lower than Claims 1-4: accused infringers must use oral MGBG and dose within 20-400 mg/day.

Claims 7, 13-19 (comparative safety outcome limitations)

Validity risk

• High if prior art provides reasons to expect similar toxicity profiles between MGBG and the comparator set, or if “reduced incidence” is not supported by comparably structured data.
• High if those toxicities were not measured or compared in the manner the claims require.

Infringement risk

• High evidentiary burden: a defendant can argue that:
  • the reduction is not relative to the enumerated comparators,
  • the incidence reduction is not established,
  • or the therapy does not show the claimed side-effect reductions.

Claims 8-12 (combination with fingolimod, dose specificity)

Validity risk

• Combination claims can be obvious if combining MGBG with an existing DMT is routine. The defense line is often “known DMT plus known adjunct.”
• However, numeric fingolimod dosing and specific reduced toxicity framing can supply differentiation if the patent’s data supports it.

Infringement risk

• Lower: the accused regimen must include fingolimod at specified doses (0.5 or 0.25 mg/day or <0.5 mg/day) plus MGBG and meet the route/dose elements depending on which claim theory is asserted.

---

Strategic read: what the patent is trying to do

The claims appear designed to do three things simultaneously:

1. Capture a new indication: MGBG for MS progression prevention (Claims 1-4).
2. Add practical prescribing constraints: oral dosing and dose range (Claims 5-6).
3. Differentiate on safety and tolerability through comparative side-effect reduction versus a curated list of DMTs (Claims 7, 13-19), then thread through combination use with fingolimod at defined doses (Claims 8-12).

From a business perspective, that combination is coherent:

• If MGBG cannot convincingly outperform on efficacy, the safety/comparator package can still support a patentable narrative.
• If MGBG’s main novelty is combination utility, the fingolimod dose-specific claims provide a narrower but enforceable commercial hook.

---

Key Takeaways

• US 10,350,178 claims an MS progression-prevention method using MGBG, with dependent claims adding oral administration, 20-400 mg/day dosing, and combination therapy with fingolimod at defined doses.
• The broadest claims are Claims 1-4, but the most enforceable in practice are the constrained subsets (oral route, numeric dosing, and fingolimod dosing).
• The most litigation-sensitive limitations are the comparative “reduced incidence” side effect claims against an enumerated DMT comparator set (Claims 7 and 13-19), which can become evidence-driven choke points for both validity and infringement.

---

FAQs

1) What is the independent claim scope?

It covers administering MGBG to a patient “in need thereof” to prevent progression of MS (Claim 1), without requiring oral route or specific dose.

2) Which claims require oral administration?

Claim 5 requires oral administration of MGBG.

3) What dosing range for MGBG is claimed?

Claim 6 recites 20 mg/day to 400 mg/day.

4) What is the role of fingolimod in the claim set?

Claims 8-12 add a fingolimod co-therapy element, with dosing specified at 0.5 mg/day (Claim 10), <0.5 mg/day (Claim 11), or 0.25 mg/day (Claim 12).

5) What makes the safety-related dependent claims hard to prove?

Claims like Claim 7 require reduced incidence of selected side effects compared to a defined list of DMTs, making enforceability dependent on comparability and evidence structure.

---

References (APA)

1. United States Patent 10,350,178 (claims provided in prompt).

Details for Patent 10,350,178

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	July 23, 1993	10,350,178	2038-08-23
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	May 17, 1996	10,350,178	2038-08-23
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	May 28, 2003	10,350,178	2038-08-23
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	February 27, 2012	10,350,178	2038-08-23
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	December 10, 1997	10,350,178	2038-08-23
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	March 07, 2002	10,350,178	2038-08-23